Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
In the phase 1 portion of the study, escalating doses of 33A will be evaluated in combination with azacitidine, and a dose of 33A will be selected to proceed to phase 2. The phase 2 portion of the study is randomized, double-blind and placebo-controlled; it is designed to compare the overall response rate (ORR) between 2 study arms.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification.
Previously untreated for Myelodysplastic Syndrome (MDS)
Age ≥18 years of age.
Eligible for therapy with azacitidine.
Life expectancy of at least 12 weeks.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Adequate baseline laboratory parameters.
You may not be if
Received prior treatment for MDS with lenalidomide or hypomethylating agents (HMAs).
History of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis.
Second malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment, eg, prostate or breast cancer).
Candidates for allogeneic stem cell transplant at the time of screening.